Vol 10, No 3 (2007)

Articles
OTsENKA VSTREChAEMOSTI ALLEL'NYKh VARIANTOV GENA RETsEPTORA KAL'TsITONINA U ZhENShchIN SO SNIZhENNOY MPK PRI GIPOESTROGENEMII
ASEEV M.V., ZAZERSKAYa I.E., KUZNETsOVA L.V., BARANOV V., AYLAMAZYaN E.K.
Abstract
Проводилась оценка встречаемости генотипов и аллелей гена рецептора кальцитонина у женщин со сниженной МПК в постменопаузальном периоде и после овариоэктомии. Изучался полиморфизм данного гена в группах наблюдения в зависимости от скорости костного обмена при гипоэстрогенемии, которая оценивалась на основании концентрации дезоксипиридинолина и степени снижения МПК за 12 месяцев исследования. достоверной разницы в распределении аллельных вариантов гена кальцитонина у женщин с высокой и низкой скоростями костного обмена как в постменопаузальном периоде, так и после овариоэктомии не обнаружено. несмотря на ожидаемую связь гена рецептора кальцитонина с риском развития остеопороза в постменопаузальном периоде, нами не получено достоверных данных, указывающих на определяющую роль данного гена в формировании костных потерь как в постменопаузе, так и у женщин после билатеральной овариоэктомии.
Osteoporosis and Bone Diseases. 2007;10(3):2-3
views
KAChESTVO ZhIZNI PRI OSTEOPOROZE. PROSPEKTIVNOENABLYuDENIE PATsIENTOV, PERENES1PIKh PERELOMPROKSIMAL'NOGO OTDELA BEDRA
LESNYaK O.M., A BAKhTIYaROVA S., GOLOBOROD'KO K.N., KUZNETsOVA N.L.
Abstract
The aim of this study was to investigate the quality of life issues among hip fracture patients. This was a comparative prospective study with the 3 years duration of follow-up. Three groups of hospitalized patients aged 50 and older were included. First group consisted of 50 hip fracture patients, second group - 45 patients with myocardial infarction, and the third group included 64 control subjects. There was no age and sex difference between groups. The Short-Form (SF-36) questionnaire was used to assess quality of life. The mortality rates as well as quality of life parameters were similar in hip fracture and myocardial infarction patients. But hip fracture patients had significantly lower values of Physical functioning and Bodily pain scores (р<0,05). In three years values of Physical functioning score and General health perception were low in both groups, but patients with hip fracture had worse meanings of Energy and Mental health scores (р<0,05). At the end of the follow-up the issues of quality of life were better in operated patients as compared to non-operated.
Osteoporosis and Bone Diseases. 2007;10(3):4-8
views
OTsENKA VLIYaNIYa PERENESENNYKh PERELOMOV LUChEVOYKOSTI NA KAChESTVO ZhIZNI ZhITEL'NITs EKATERINBURGA,STRADAYuShchIKh POSTMENOPAUZAL'NYM OSTEPOROZOM
POPOV A.A., IZMOZhEROVA N.V., GAVRILOVA E.I., FOMINYKh M.I.
Abstract
Aim: to assess quality of life (QOL) of postmenopausal women with osteoporosis (OP) complicated by distant forearm fracture (DFF) in comparison with QOL of women with normal bone mineral density (BMD) and non-complicated OP. Methods: this case control study included 30 women with normal BMD, 30 persons with non-complicated OP and 30 patients with OP, complicated by DFF. SF-36 questionnaire was used to assess QOL.. Results: DFF was associated with restrictions in physical functioning in comparison to other groups (Р<0,0001). Both ВАА and non complicated OP groups showed lower levels of role physical functioning (Р<0,0001), social functioning (Р<0,0001), role emotional limitations (Р<0,0001) in comparison with normal BMD group, but there were no differences in bodily pain (Р=0,079) and general health perception (Р=0,11). Non-complicated OP group had higher levels of energy/vitality and mental health scales than those in DFF (Р=0,033) and normal BMD (Р<0,0001) groups. Thus, DFF causes significant restrictions of QOL in postmenopausal women.
Osteoporosis and Bone Diseases. 2007;10(3):9-11
views
SOSTOYaNIE KOSTNOY TKANI I RISK RAZVITIYa OSTEOPOROZA U ZhENShchIN V STADII POLNOY REMISSIIBOLEZNI ITsENKO-KUShINGA NA FONE FIZIOLOGIChESKOYMENOPAUZY
MARChENKOVA L.A., DREVAL' A.V., POLYaKOVA E.Y., TIShENINA R.S., MYLOV N.M., ERMAKOVA I.P., PRONChENKO I.A., BUZULINA V.P., RUBIN M.P.
Abstract
It is well known that clinical signs of endogenous hypercorticism including secondary osteoporosis rapidly reverse on the base of hormonal remission after radiosurgical treatment of Cushing's disease (CD). The aim of the study was to assess BMD and bone turnover biochemical markers in postmenopausal women with complete CD-remission. We examined 43 women aged 38-67 years in physiological postmenopause who had a complete long-term hormonal CD-remission for at least 2 years (11±6,8 years in average) after combine treatment with hemiadrenalectomy and radiosurgery. Control group comprised 98 healthy postmenopausal women at the same age and postmenopausal age. Our main findings were BMD in postmenopausal CD-patients was higher vs. controls in lumbar spine (1,233±0,17 vs. 1,146±0,20 g/cm2, p<0,05), trochanter (0,873±0,15 vs. 0,809±0,15 g/cm2, p<0,05) and total proximal femur (1,067±0,16 vs. 0,949±0,21 g/cm2, p<0,01). Frequency of normal BMD was significantly higher in spine (93%), trochanter (93%), total proximal femur (93%) and distal forearm (81%) in CD-group vs. control (62%, 76%, 77% and 59% accordingly, p<0,05). There was also revealed a lower frequency of osteopenia in spine (14%), trochanter (7%) and distal forearm (14%) in CD-group vs. control (32%, 23% and 33% accordingly, p<0,05), although incidence of vertebral deformities were more in CD-group (37%) vs. control (18%, p<0,05). We found significantly lower levels of CTx (p<0,001) and osteocalcin (p<0,01) in CD-patients vs. controls. A maximal BMD gain was observed in patients with CD remission about 4-5 years and BMD significantly decreased in women with CD-remission more than 12 years. CD-women with postmenopausal age 2-10 years had significantly higher BMD vs. associate control postmenopausal women. Marked BMD lowering was observed in CD-women only after 10 years of menopause. Age, postmenopausal age, low body weight and duration of remission were evaluated as main risk factors for osteoporosis in women with complete CD-remission. Our result demonstrate that postmenopausal women with complete CD-remission have higher BMD and lower bone turnover than healthy postmenopausal women of the same age and maximal increase in BMD is observed at about 5 years of complete CD-remission.
Osteoporosis and Bone Diseases. 2007;10(3):13-20
views
PROFILAKTIKA NARUPENI OBMENA KAL'TsIYa I SISTEM EGO REGULYaTsII PRI DLITEL'NOY GIPOKINEZII S UChASTIEM ChELOVEKA
ORLOV O.I.
Abstract
In conditions of 120-daily bedrest changes of a metabolism of the calcium, the functions of a bone directed on preservation at a necessary level of a bone material at the maximal economy level in these conditions were studied. The applied preventive complex consisting of xydyphone and special physical trainings, has rendered the expressed influence on a condition of a calcium homeostasis, defined, on the studied parameters, basically, by diphosphonates.
Osteoporosis and Bone Diseases. 2007;10(3):21-23
views
REZUL'TATY ROSSIYSKOGO MNOGOTsENTROVOGO ISSLEDOVANIYa EFFEKTIVNOSTI I PERENOSIMOSTIBIVALOSA (STRONTsIYa RANELATA) U ZhENShchINS POSTMENOPAUZAL'NYM OSTEOPOROZOM
ROZhINSKAYa L.Y., ARAPOVA S.D., DZERANOVA L.K., MOLITVOSLOVOVA N.N., MAROVA E.I., ShIShKINA A.A., SAZONOVA N.I., ChERNOVA T.O., IL'IN A.V., BENEVOLENSKAYa L.I., NIKITINSKAYa O.A., KOROTKOVA T.A., TOROPTsOVA N.V., SMIRNOV A.V., DEMIN N.V., RODIONOVA S.S., BUKLEMEShEV Y.V., ShUMSKIY A.A.
Abstract
В представляемой работе обобщен первый опыт применения Бивалоса в терапии ПМО в России. Целью настоящего исследования являлось изучение влияния терапии Бивалосом в течение года на МПК позвоночника, МПК шейки бедра и бедренной кости в целом, уровень маркеров костного метаболизма, а также на качество жизни и переносимость длительной терапии у пациенток с ПМО. В исследование включено 60 женщин от 55 до 75 лет с ПМО, проходивших лечение в 3 медицинских центрах г. Москвы (ЭНЦ, ИР РАМН, ЦИТО - по 20 пациенток в каждом центре). Через год применения Бивалоса отмечено достоверное увеличение МПК в поясничных позвонках на 4,68±4,94%, в шейке бедра на 2,0±4,29% и по общему показателю МПК проксимального отдела бедренной кости на 3,10±3,34%. Оценка динамики маркеров костного метаболизма выявила статистически значимый прирост КЩФ на 19,5% и снижение СТх на 16,4%, что подтверждает разнонаправленный эффект Бивалоса на костеобразование и резорбцию костной ткани. Терапия Бивалосом повышает качество жизни пациентов: расширяет двигательную активность, снижает уровень депрессии, повышает самооценку, уменьшается количество пациентов с болью в спине, снижаются уровень боли и частота ее возникновения. Бивалос хорошо переносится пациентами, частота НЯ, связанных с приемом препарата, не превышает 15%, а отмена препарата из-за НЯ составила 5%. Не наблюдалось серьезных побочных явлений. Наши результаты сходны с данными многоцентровых двойных слепых плацебо-контролируемых исследований с большой статистической мощностью.
Osteoporosis and Bone Diseases. 2007;10(3):24-30
views
IZUChENIE PERENOSIMOSTI ALENDRONATA 70 MG (FOSAMAKS 70 MG ODIN RAZ V NEDELYu) I PRIChINOTMENY LEChENIYa U BOL'NYKh POSTMENOPAUZAL'NYMOSTEOPOROZOM V USLOVIYaKh REAL'NOY KLINIChESKOYPRAKTIKI
LYaLINA V.V., MYLOV N.M., DMITRIEVA E.G., KORVYaKOV E.L.
Abstract
The aim of study was tolerability and causes of discontinuation to alendronate 70 mg OW therapy in nonresearch real world setting. We prospectively analyzed 427 female patients (67+8,2years) newly prescribed with alendronate 70mg OW for postmenopausal osteoporosis and followed up during a year. The background of GI diseases was reported in 64% of patients, while 36% were receiving three or more concomitant medications. 30% of patients discontinued therapy throughout the year. The most frequent reasons for treatment discontinuation were unaffordable price of alendronate (20% of all patients; 68% of all discontinuation cases) and GI complaints (9%;29,6%), despite most cases were not assumed to be related to the drug. There were only 3 cases of intolerance to alendronate (0,7%;2,3%). In persistent patients alendornate was overall well tolerated; in 22% of them minor or mild dyspepsia was reported. The incidence of dyspepsia was not associated with the presence of GI diseases (p=0,953). The study suggests that a large proportion of GI adverse experiences seen on aledronate treatment may not have causal relationship to therapy. The high rate of GI diseases and concomitant drugs in osteoporosis patients are underestimated in clinical practice.
Osteoporosis and Bone Diseases. 2007;10(3):31-35
views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies